1. Home
  2. APVO

as of 02-13-2026 1:07pm EST

$6.70
+$0.11
+1.67%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Founded: 2016 Country:
United States
United States
Employees: N/A City: SEATTLE
Market Cap: 8.3M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 61.9K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -351.39 EPS Growth: N/A
52 Week Low/High: $5.94 - $1439.96 Next Earning Date: 02-20-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: -26115000.0 FCF Growth: N/A

AI-Powered APVO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 4 days ago

AI Recommendation

hold
Model Accuracy: 72.78%
72.78%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: